Molecular Markers of Schizophrenia, VR vs Anxiety, and Legendary Past of Psychiatric Hospitals' in Consortium Psychiatricum Journal
The first issue of Consortium Psychiatricum in 2023 is out of press. It focuses on a wide range of mental health topics: biomarkers of mental disorders, new non-pharmacological therapies, and drug combinations in pharmacological therapy.
Molecular markers of schizophrenia in the brain are analyzed in a study by scientists from the Skolkovo Institute of Science and Technology and their co-authors. Changes in the expression of long non-coding RNAs were found in brain areas previously overlooked by transcriptome researchers.
The effectiveness of treatment of depression in schizophrenia with second-generation antipsychotics and vortioxetine is discussed in the article provided by the research teams of Mental-health Clinic No. 1 named after N.A. Alexeev, Mental-health Clinic No. 4 named after P.B. Gannushkin and their colleagues.
Researchers from the Mental Health Research Center and the Speech Pathology and Neurorehabilitation Center in Moscow studied the effectiveness of virtual reality for symptoms of anxiety and asthenia in somatic inpatients.
A narrative literature review by researchers of the Mental-health Clinic No. 1 named after N.A. Alexeev and Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
focuses on the methods for diagnosing cognitive decline and Alzheimer's disease using biological markers.
A new informational section highlights the most important milestones in the development of psychiatric care in Russia. The first material of the section tells the story of one of the oldest psychiatric hospitals, the Moscow Mental-health Clinic No. 4 named after P. B. Gannushkin.
The full texts of all the articles are available on the Consortium Psychiatricum website.
You might also be interested to see Consortium Psychiatricum's interviews with the co-authors of a study recently published in JAMA Psychiatry: Lipid Alteration Signature in the Blood Plasma of Individuals With Schizophrenia, Depression, and Bipolar Disorder. Olga Karpenko, deputy editor-in-chief of the journal, talked to representatives of the Mental Health Research Center - Professors Klyushnik and Barkhatova - and the Skolkovo Institute of Science and Technology - Professor Khaitovich and his research team.